Document:

<PAGE>

Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                                                   Exhibit 10.19

                 RESEARCH COLLABORATION AND LICENSE AGREEMENT

     This Research Collaboration And License Agreement (the "Agreement") is made
by and between The R. W. Johnson Pharmaceutical Research Institute, a division
of Ortho-McNeil Pharmaceutical, Inc., having a business address at U.S. Route
202, Raritan, New Jersey 08869 ("PRI") and Dendreon Corporation, having a
business address at 3005 1st Avenue, Seattle, Washington 98121 ("Dendreon").

     Whereas, PRI owns or controls [ * ] technology for [ * ], [ * ] peptide
antigen constructs and related materials; and

     Whereas, Dendreon owns or controls dendritic cell technology for Her-2/neu,
[ * ] antigen constructs and related materials; and

     Whereas, PRI and Dendreon desire to determine the feasibility of their
respective technologies as immunotherapy products for the treatment of tumors
which express Her-2/neu, including breast cancer, ovarian cancer and colorectal
cancer, with a view toward the possibility of a future collaboration to
determine the feasibility of a such a product made by combining their respective
technologies;

     Now Therefore, it is agreed as follows:

1.   Purposes.  The purposes of this Agreement are to provide for studies of the
PRI Technology and of the Dendreon Technology to determine their feasibility,
respectively, as immunotherapy products for the treatment of tumors which
express Her-2/neu, including breast cancer, ovarian cancer and colorectal cancer
by performing Phase I Clinical Trials, and to consider the feasibility of
combining the PRI Technology and the Dendreon Technology for development and
commercialization of such a product in a future collaboration.

2.   Effective Date.  This Agreement is effective as of October 1, 2000 (the
"Effective Date").

3.   Term.  This Agreement is for a term beginning on October 1, 2000 and ending
at 11:59 pm PST on [ * ].

4.   Definitions.

     4.1  "Affiliate" means, with respect to a Party, any person or entity that
controls, is controlled by, or is under common control with such Party, where
"control" means ownership of fifty percent (50%) or more of the outstanding
voting securities (but only as long as such person or entity meets these
requirements).

                                       1.
<PAGE>

     4.2  "Clinical Trials" means the clinical studies of human subjects
described in the Collaboration Research Plan.

     4.3  "Collaboration" means the work to be performed by the Parties under
this Agreement.

     4.4  "Collaboration Research Plan" means the work plan to be performed
under this Agreement as set forth in Schedule A.

     4.5  "Confidential Information" means information as defined in Section
7.5.

     4.6  "Control or Controlled" means, with respect to Technology, that a
Party owns or has a license to such Technology and has the ability to grant to
the other Party access to or a license or sublicense under such technology
without violating the terms of any agreement with a Third Party at the time of
the grant.

     4.7  "Dendreon Patents" means those:

          (i) granted patents and patent applications set forth in Schedule B-1,

          (ii) Third Party patents set forth in Schedule B-1, and

          (iii) any other patent, patent application, and Third Party patent in
which Dendreon, in its sole discretion, may from time to time add to Schedule B-
1, subject to the [ * ], in which Dendreon has a licensable interest, to the
extent such granted patents, patent applications and Third Party patents may
apply in the Field.

     4.8  "Dendreon Technology" means the Dendreon Patents and other Technology
that is Controlled by Dendreon and which is appurtenant to Dendreon's antigen
activated dendritic cell product for the treatment of Her-2 positive tumors
(APC8024), Dendreon's Investigational New Drug application for APC8024, and
dendritic cell antigen engineering technology and know-how, cell separation
technology, related materials and know-how specifically germane to the treatment
of Her-2 positive tumors.

     4.9 "Developed Technology" means granted patents, patent applications and
other Technology developed in the course of the work under this Agreement,
[ * ].

     4.10 "FDA" means the U.S. Food and Drug Administration.

     4.11 "Field" means the treatment of cancers which express the Her-2/neu
antigen using Dendreon Technology or PRI Technology directed to the Her-2/neu
antigen as the therapeutic target.

     4.12 "FTE" means work hours equivalent to the work performed by one full
time employee working for one year, pursuant to Dendreon's usual and customary
business practices.

     4.13  "IND" means Investigational New Drug.

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       2.
<PAGE>

     4.14 "Party" or "Parties" means PRI and/or Dendreon as the context
requires.

     4.15  "PRI Patents" means those:

          (i) granted patents and patent applications set forth in Schedule B-2,

          (ii) Third Party patents set forth in Schedule B-2, and

          (iii) any other patent, patent application, and Third Party patent
which PRI, in its sole discretion, may from time to time add to Schedule B-2,
subject to the [ * ], in which PRI has a licensable interest, to the extent such
granted patents, patent applications and Third Party patents may apply in the
Field.

     4.16  "PRI Technology" means the PRI Patents and other Technology that is
Controlled by PRI and which is appurtenant to [ * ] for generation of activated
[ * ] against [ * ], [ * ] peptide antigens, related materials and know-how
specifically germane to the treatment of [ * ] tumors.

     4.17 "Research Steering Committee" means a committee composed of three PRI
designees and three Dendreon designees, or such other number as the Parties may
agree in writing, whose function is set forth in Section 7.1.

     4.18 "Technology" means conceptions, ideas, inventions, processes,
equipment, compositions of matter, genetic material, work plans, improvements,
enhancements, modifications, know-how, methods, techniques, systems, designs,
drawings, plans, specifications, documentation, data, information and other
intellectual property, works of authorship, and products, whether or not
copyrightable, patentable or susceptible to other forms of legal protection.

     4.19  "Territory" means all of the countries in the world except [ * ].

     4.20  "Third Party" means any party other than PRI and Dendreon.

5.   PRI's Responsibilities and Rights.

     5.1 License. PRI hereby grants to Dendreon an exclusive, non-assignable
license to the PRI Technology, without the right to sub-license, in the Field in
the Territory, for the sole purpose of conducting the work set forth in the
Collaboration Research Plan during the term of this Agreement; provided however,
PRI shall retain the right to conduct the work set forth in the Collaboration
Research Plan. This license shall [ * ] upon the expiration or termination of
this Agreement.

     5.2 Study Fee. PRI shall pay to Dendreon a study fee in the sum of [ * ] US
Dollars [ * ] within [ * ] days after the Effective Date.

     5.3 Milestone Payment. PRI shall pay to Dendreon the sum of [ * ] US
Dollars [ * ] within [ * ] days after acceptance by the U.S. FDA of Dendreon's
IND application for APC8024 filed with the U.S. FDA under the Collaboration
Research Plan.

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       3.
<PAGE>

     5.4  FTE Reimbursement.  PRI shall pay to Dendreon the sum of [ * ] US
Dollars [ * ] for each FTE provided for in the Collaboration Research Plan. PRI
shall pay to Dendreon [ * ] US Dollars [ * ] within [ * ] days after the
Effective Date for FTE reimbursement for the period [ * ] through [ * ].
Thereafter, FTE reimbursement payments shall be made within [ * ] days after
receipt of respective quarterly invoices rendered by Dendreon to PRI.

     5.5  Capital Items.  PRI shall pay to Dendreon, [ * ] US Dollars [ * ]
within [ * ] days after the Effective Date for purchase by Dendreon on behalf of
PRI of all capital items as provided for in the Collaboration Research Plan.
Dendreon, on behalf of PRI, shall purchase all capital equipment identified in
the Collaboration Research Plan in amounts not to exceed [ * ], and all right,
title and interest to such capital equipment shall be in PRI. At the expiration
or termination of this Agreement, all such equipment shall be shipped by
Dendreon to PRI at such location specified by PRI, f.o.b. site of the equipment,
at PRI's expense.

     5.6  Expense Reimbursement.  PRI shall pay to Dendreon, within thirty (30)
days after receipt of respective invoices rendered by Dendreon to PRI, amounts
spent by Dendreon for contract costs as provided for in the Collaboration
Research Plan.

     5.7  Cooperation.  PRI shall, at its expense, cooperate fully in all
respects with Dendreon in the performance of the work under the Collaboration
Research Plan.

     5.8  Disclaimer of Warranties.  PRI makes NO, AND DISCLAIMS ANY AND ALL
WARRANTIES OR REPRESENTATIONS OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT
LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE,
and non-infringement with respect to PRI Technology, except PRI represents that
there is no claim of infringement and that it knows of no infringement with
respect to the PRI Technology as of the Effective Date.

     5.9  Indemnity.  PRI shall indemnify, defend and hold Dendreon harmless
from and against claims by Third Parties, related expenses, including reasonable
attorney's fees, and for damages payable to Third Parties arising out of or
resulting from PRI's conduct, breach of this Agreement and/or infringement of a
Third Party's patent or other intellectual property that results from Dendreon's
work pursuant to the Collaboration Research Plan under the license granted in
Section 5.1.

     5.10  Notice of Infringement Claims.  PRI shall promptly notify Dendreon of
any claim of infringement of a patent or other intellectual property which is
PRI Technology.

     5.11  Audit.  PRI may audit and inspect the work being done by Dendreon
under the Collaboration Research Plan and related records at any time following
reasonable notice to Dendreon of PRI's intent to audit and inspect.

6.   Dendreon's Responsibilities and Rights.

     6.1  License.  Dendreon hereby grants to PRI an exclusive non-assignable
license to the Dendreon Technology, without the right to sub-license, in the
Field in the Territory, for the sole purpose of conducting the work set forth in
the Collaboration Research Plan during the term

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       4.
<PAGE>

of this Agreement; provided however, Dendreon shall retain the right to conduct
the work set forth in the Collaboration Research Plan. This license shall [ * ]
upon the expiration or termination of this Agreement.

     6.2  Conduct of the Work.  Dendreon shall undertake and conduct the work,
including the Clinical Trials, as set forth in the Collaboration Research Plan
in accordance with appropriate standards articulated in current good clinical
practices (GCP), current good manufacturing practices (GMP) and current good
laboratory practices (GLP). Dendreon will use reasonable efforts to carry out
the work in accordance with the Collaboration Research Plan.

     6.3  Cooperation.  Dendreon shall cooperate fully in all respects with PRI
in the performance of the work under the Collaboration Research Plan.

     6.4  Disclaimer of Warranties.  Dendreon makes NO, AND DISCLAIMS ANY AND
ALL WARRANTIES OR REPRESENTATIONS OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING
WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE, and non-infringement with respect to Dendreon Technology, except
Dendreon represents that there is no claim of infringement and that it knows of
no infringement with respect to the Dendreon Technology as of the Effective
Date.

     6.5  Insurance.  Dendreon shall maintain property and casualty insurance
covering the capital equipment purchased by Dendreon on behalf of PRI in an
amount not less than [ * ] US Dollars [ * ], naming PRI as a loss payee to the
extent of its interest in such capital equipment. Dendreon shall cause its
insurance policies to be endorsed to provide for [ * ] days' prior written
notice to PRI by the insurance carrier of cancellation, expiration or
modification of the insurance policy, and will furnish to PRI certificates of
insurance evidencing the foregoing within ninety (90) days after the Effective
Date.

     6.6  Indemnity.  Dendreon shall indemnify, defend and hold PRI harmless
from and against claims by Third Parties, related expenses, including reasonable
attorney's fees, and for damages payable to Third Parties arising out of or
resulting from Dendreon's conduct, breach of this Agreement and/or infringement
of a Third Party's patent or other intellectual property that results from PRI's
work pursuant to the Collaboration Research Plan under the license granted in
Section 6.1.

     6.7  Notice of Infringement of Claims.  Dendreon shall promptly notify PRI
of any claim of infringement of a patent or other intellectual property which is
Dendreon Technology.

7.  Mutual Responsibilities and Rights.

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       5.
<PAGE>

     7.1  Research Steering Committee.  The Research Steering Committee shall
manage and direct the work under the Collaboration Research Plan and may modify
the Collaboration Research Plan.

          7.1.1  Unanimous Decisions.  Decisions of the Research Steering
Committee may be made only unanimously, with each of PRI and Dendreon having one
vote.

          7.1.2  Expenses.  Expenses of the Parties' designees to the Research
Steering Committee shall be borne by [ * ].

          7.1.3  Meetings.  The Research Steering Committee shall meet at such
times and places as it shall determine at least four times a year.

          7.1.4  Advice as to Future Collaboration.  Not later than [ * ], the
Research Steering Committee shall advise the Parties in writing as to any view
the committee may have of the feasibility of future collaboration by the Parties
with respect to the Parties' respective separate and/or combined technology. The
Research Steering Committee may include in its advice recommendations as to the
general content of a future research and development plan, clinical studies, and
other terms of a future collaboration.

          7.1.5  Program Coordinators.  Dendreon and PRI shall each identify one
program coordinator with relevant experience and credentials to coordinate the
efforts of the Research Steering Committee as set forth in this Section 7 (the
"Program Coordinators"). Dendreon and PRI shall designate their respective
Program Coordinators within ten (10) days after the Effective Date and inform
each other of such designation in writing within such time period. Either Party
may replace its Program Coordinator, at its discretion, with another individual
with appropriate experience and credentials. Each Party will promptly provide
written notice to the other if it replaces its Program Coordinator.

     The Program Coordinators shall be responsible for: (i) coordinating the
activities of the Research Steering Committee; (ii) conducting and coordinating
reviews of the Collaboration Research Plan; (iii) proposing revisions to the
Collaboration Research Plan to the Research Steering Committee; (iv)
communicating on a regular basis by telephone, facsimile, email, video
conference, internet conferencing and/or in person to review progress, track
schedules, resolve problems and arrange for the exchange of materials or
information necessary for the performance of the Collaboration in accordance
with the Collaboration Research Plan; (v) scheduling Research Steering Committee
meetings and creating agendas therefore mutually acceptable to the Parties; and
(vi) representing the position of their respective Party with respect to
Research Steering Committee decisions and actions.

          7.1.6  Establishment of Research Steering Committee.  The Parties
shall establish within ten (10) days after the Effective Date the Research
Steering Committee to manage, discuss, oversee, direct, and provide input with
regard to the status, progress and results of the Collaboration. Each Party
shall inform the other of its Research Steering Committee designees in writing
within such time period. The Program Coordinators shall be the co-chairs of the
Research Steering Committee. Subject to the approval of the Program
Coordinators, each Party may invite any of its employees or approved contractors
with relevant experience to attend

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       6.
<PAGE>

and participate in Research Steering Committee meetings in a non-voting
capacity. The Program Coordinators shall jointly create written summary reports
reflecting matters discussed, input provided, decisions made and actions taken
at Research Steering Committee meetings, and such reports shall be prepared
promptly after each meeting and provided to the members of the Research Steering
Committee.

          7.1.7  Method of Modification of Collaboration Research Plan.  Any
modification of the Collaboration Research Plan requested by either Party,
including but not limited to Third Party licenses, shall be made in a written
proposal to the Research Steering Committee. The Research Steering Committee
will determine whether implementing the requested change will result in a delay
in the schedule for the Collaboration or have other impact on the Collaboration.
If the Research Steering Committee unanimously approves the proposed change, the
Collaboration Research Plan will be modified to reflect the change. PRI shall
have no obligation to provide additional funding for the work beyond the amounts
set forth in Schedule A without the prior written approval of PRI.

     7.2  Future Collaboration, Right of First Negotiation.  Not later than
[ * ], the Parties shall endeavor to agree upon the feasibility of a future
collaboration using their respective separate and/or combined technology,
including potential terms of an agreement with respect thereto, contemplated to
be entered into following completion and evaluation of the Clinical Trials and
to [ * ]. Nothing herein shall [ * ] Agreement.

     7.3  Standstill.  Each of the Parties agrees that [ * ] it shall not enter
into any negotiations related to a potential agreement for the purpose of
performing [ * ] without the prior written consent of the other Party. Such
negotiations and agreements do not include any Third Party agreement for the
purpose of performing the work under this Agreement.

     7.4  Compliance with Laws and Regulations.  PRI and Dendreon shall,
respectively, comply with all applicable laws and regulations in the performance
of this Agreement.

     7.5  Confidentiality.  Except as provided below, and except as provided in
Schedule C, PRI and Dendreon shall maintain the other's proprietary information
in confidence and shall not disclose it to any Third Party and shall use it only
to the extent reasonably necessary to carry out the terms of this Agreement.
Each Party may from time to time during the term of this Agreement disclose (the
"Disclosing Party") to the other Party (the "Receiving Party") certain
information not generally available to the public regarding the Disclosing
Party's business, including PRI Technology, Dendreon Technology, Developed
Technology, information relating to business plans furnished by one Party to the
other, and other information relating to the Collaboration or Field furnished by
one Party to the other in the course of the work under this Agreement
("Confidential Information"). No Confidential Information shall be disclosed to
any officer, employee, agent, or Affiliate of the Receiving Party who does not
have a need to know such information for the purposes described herein or for
conducting the business of the Receiving Party and who is not bound by a written
agreement with the Receiving Party to maintain Confidential Information in
confidence under the terms no less burdensome than those set forth herein. The
obligations set forth in this Section 7.5 shall survive for a period of five (5)
years after the termination or expiration of this Agreement.

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       7.
<PAGE>

          7.5.1  Exceptions to Non-disclosure of Confidential Information.  The
Receiving Party may make disclosures of Confidential Information which may be
required by law, regulation, or court or administrative order, provided that the
Receiving Party: (a) uses reasonable efforts to limit the disclosure of
Confidential Information consistent with disclosure requirements; (b) seeks to
obtain the appropriate confidential treatment or a protective order protecting
any further disclosure of Confidential Information; and (c) makes such
reasonable efforts as are reasonably practicable under the circumstances to
allow Disclosing Party to seek the opportunity to protect its Confidential
Information.

          7.5.2  Exclusions from Confidential Information.  The definition of
Confidential Information will exclude that which is (a) in the public domain at
the time of disclosure hereunder or which subsequently has come within the
public domain other than through breach of this Agreement by the Receiving
Party, (b) lawfully made available to the Receiving Party by an independent
party (and such lawful availability can be properly demonstrated by written
records), (c) already in the Receiving Party's possession at the time of the
initial receipt (and such prior possession can be properly demonstrated by
written records), or (d) independently developed by the Receiving Party without
use of or reliance on the Confidential Information.

     7.6  Publication.  Neither PRI nor Dendreon shall publish any human
clinical data relating to the Clinical Trials without the prior written consent
of the other Party. Upon such written consent, and with respect to the
publication of any other information relating to the Collaboration, the Party
intending to publish shall provide the other with a copy of the proposed
presentation or publication at least forty-five (45) days prior to submission
for publication or presentation. The Party intending to publish shall, at the
other's request, exclude or delete matter reasonably designated by the other
from the proposed publication or presentation. Notwithstanding the foregoing,
the Parties shall use reasonable efforts to ensure sufficient time prior to any
publication of any data generated during performance of the Collaboration to
allow filing of patent applications.

     For Clinical Trials that are performed by a Third Party, Dendreon shall
make a reasonable effort to obtain agreement with the Third Party to not publish
the result of the Clinical Trial without the prior written consent of Dendreon.
In the event that Dendreon does not obtain such agreement with a Third Party,
the Third Party may be permitted to publish the results of the Clinical Trial
actually performed by the Third Party, provided that Dendreon will submit to PRI
drafts of all proposed publications relating to the Clinical Trials, and any
know-how or patent rights relating to such Clinical Trials, at the earliest
possible date, but in any event not less than forty-five  (45) days prior to the
submission of said proposed publications for publication or presentation.  PRI
shall have the right to advise Dendreon as to the patentability of any invention
disclosed therein, and to request the filing of a patent application.  Dendreon
shall prepare and file any such patent application prior to the submission of
the proposed publication for publication or presentation.  At the end of such
forty-five  (45) day period, the Third Party shall have the right, at its sole
discretion, to submit such proposed publications for publication or
presentation, but [ * ].

     Except with respect to [ * ], the foregoing limitations on publication
shall not apply to [ * ].

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       8.
<PAGE>

     7.7  Publicity.  Dendreon and PRI contemplate announcing the execution and
delivery of this Agreement shortly after its signing. However, except as may be
required by law, regulation, or court or administrative order, neither Party
shall originate any publicity, news release or other public announcement or
disclosure, written or oral, whether relating to the performance under or
existence of this Agreement, without the prior written consent of the other
Party, which shall not be unreasonably withheld; provided, however, if public
disclosure is or may be required by law, regulation, or court or administrative
order, the parties shall, as is reasonably practicable under the circumstances,
consult with one another in connection with such disclosure a reasonable time
under the circumstances prior to its release to allow the other Party to comment
thereon. Notwithstanding anything else in this Section 7.7, Dendreon may, after
initial approval of any disclosure by PRI, publicly disclose thereafter such
approved information from time to time. The publicity and disclosures set forth
on Schedule C are approved by the Parties.

     7.8  Trade Marks and Trade Names.  Neither PRI nor Dendreon is authorized
to use the other's name or mark in any advertisement.

     7.9  Disposition of Technology Upon Expiration or Termination of This
Agreement.

          7.9.1  PRI Technology.  Upon expiration or termination of this
Agreement, PRI shall solely have and retain the PRI Technology, and Dendreon
shall have no rights or interest therein.

          7.9.2  Dendreon Technology.  Upon expiration or termination of this
Agreement, Dendreon shall solely have and retain the Dendreon Technology, and
PRI shall have no rights or interest therein.

          7.9.3  Developed Technology.  Upon the expiration or termination of
this Agreement, the Parties shall identify with specificity any Developed
Technology and shall [ * ], provided however that (i) PRI shall not be permitted
to use or disclose to any Third Party Developed Technology which was directly
derived from Dendreon Technology without the express written consent of
Dendreon, and (ii) Dendreon shall not be permitted to use or disclose to any
Third Party Developed Technology which was directly derived from PRI Technology
without the express written consent of PRI.

     7.10  Patents.  The Parties shall [ * ] the expense of filing, prosecuting
and defending patents that claim Developed Technology. In the event of
infringement of Developed Technology by an unauthorized Third Party, the Parties
shall agree on how to abate such infringement. In the event the Parties jointly
litigate any infringement of Developed Technology by a Third Party, the Parties
shall [ * ] in the expenses of such litigation and shall [ * ] in any recovery.
If the Parties do not jointly litigate any infringement of Developed Technology
by a Third Party, either Party may independently litigate such infringement at [
* ] and shall be entitled to [ * ].

     7.11  Non-Solicitation of Employees.  Neither PRI nor Dendreon shall
directly or indirectly, alone or in concert with others, employ or solicit for
employment any employee of the

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       9.
<PAGE>

other Party during the term of this Agreement and for one year after the
termination or expiration thereof.

8.   Generally Applicable Provisions.

     8.1  Counterparts.  This Agreement may be executed in counterparts.

     8.2  Entire Understanding.  This Agreement represents the entire
understanding between PRI and Dendreon with respect to the subject matter of
this Agreement, and supercedes any implied or expressed agreement or
understanding between them.

     8.3  Force Majeure.  Neither PRI nor Dendreon shall be liable for failure
to perform under this Agreement if the failure results from a cause beyond the
control of the failing party, such as an act of God, fire, strike, flood, riot
or act of war; provided, that the failing Party shall use reasonable efforts to
avoid or remove such cause, and upon removal shall resume performance.

     8.4  No Assignment and Binding on Successors.  Except to the extent PRI may
assign its responsibilities and rights hereunder to an Affiliate of PRI
following at least thirty (30) days prior written notice to Dendreon of PRI's
intent to do so, this Agreement and the responsibilities and rights hereunder
undertaken by and granted to the Parties may not be assigned by either Party, or
the work hereunder sub-contracted by Dendreon without the prior written consent
of the other Party, such consent not to be unreasonably withheld. This Agreement
shall be binding on the Parties' respective successors and permitted assigns.

     8.5  No Partnership.  This Agreement is not intended to make, and shall not
be construed to make, PRI and Dendreon the agent, partner or co-venturer of the
other.

     8.6  No Waiver.  Failure to enforce at any time for any period any
provision in this Agreement shall not be construed to be a waiver of such
provision or the right to enforce such provision.

     8.7  Notices.  Notices required by this Agreement shall be in writing and
made by first class mail, postage prepaid, or facsimile.

          Notice to be given to PRI, if by mail, shall be addressed to:

          The R. W. Johnson Pharmaceutical Research Institute
          U.S. Route 202
          Raritan, New Jersey 08869 Phone: 908-704-4520
          Attention: Chairman, The R. W. Johnson Pharmaceutical Research
          Institute

          Or, if by facsimile, to Chairman, at (908) 707-1895

          With a copy to:

          Office of General Counsel
          Johnson & Johnson

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                      10.
<PAGE>

          One Johnson & Johnson Plaza
          New Brunswick, New Jersey 08933
          Fax:  732-524-2808
          Phone: 732-524-2368

          Invoices should be addressed to:

          The R. W. Johnson Pharmaceutical Research Institute
          3210 Merryfield row
          San Diego, California 92121
          Attention:  Dr. Michael R. Jackson
          Phone: (859) 450-2000

          Notice to be given to Dendreon, if by mail, shall be addressed to:

          Dendreon Corporation
          3005 1st Avenue
          Seattle, Washington 98121
          Phone: (206) 256-4545
          Attention:  David L. Urdal, Executive Vice President

          Or, if by facsimile, to David L. Urdal at (206) 256-0571.

     8.8  Surviving Provisions.  Sections 5.8, 5.9, 5.10, 5.11, 6.4, 6.6, 6.7,
7.5, 7.6, 7.7, 7.9.3, 7.10, 7.11, 8.7, 8.8, and 10 shall survive the expiration
or termination of this Agreement.

9.   Procedure Upon Default.  The failure of a Party to pay any amounts when due
hereunder or the failure of a Party to perform any obligation required of it to
be performed hereunder, and the failure to cure within sixty (60) days after
receipt of written notice from the other Party specifying in reasonable detail
the nature of such default, shall be considered an event of default hereunder.
Upon the occurrence of an event of default and the failure to cure during the
sixty (60) days after receipt of notice, either Party may deliver to the other
Party written notice of intent to invoke the provisions of Section 10.

     9.1  Termination by PRI.  PRI shall have the right to terminate this
Agreement if the result of the arbitration is that there has been a material
breach by Dendreon, by providing written notice of such termination to Dendreon.
Any payment obligations of PRI that have accrued prior to the date of such
notice of termination shall be paid by PRI. PRI shall not be obligated to make
any payments to Dendreon that would accrue after the receipt by Dendreon of
PRI's termination notice.

     9.2  Termination by Dendreon.  Dendreon shall have the right to terminate
this Agreement, if the result of the arbitration is that there has been a
material breach by PRI, by providing written notice of such termination to PRI.
Any performance obligations of Dendreon that have accrued prior to the date of
such notice of termination shall be completed by Dendreon. Dendreon shall not
have any performance obligations to PRI after the receipt by PRI of Dendreon's
termination notice.

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                      11.
<PAGE>

10.  Dispute Resolution and Governing Law.  Should any dispute between the
parties arise under this Agreement, PRI and Dendreon, through appropriately
senior persons, shall first meet and attempt to resolve the dispute in face-to-
face negotiations. This meeting shall occur within 30 days after written notice
of a dispute is received by either Party from the other Party.

     If no resolution is reached through negotiation, PRI and Dendreon shall,
within 45 days after the first meeting, attempt to settle the dispute by formal
mediation. If the parties cannot agree upon a mediator and the place of
mediation, the mediation shall be administered by the American Arbitration
Association in Seattle, Washington.

     If no resolution is reached in mediation, the dispute shall be resolved by
binding arbitration before one arbitrator, administered by the American
Arbitration Association, in accordance with its Commercial Arbitration Rules,
with limited discovery. The arbitrator shall be an attorney who has at least 15
years of experience with a law firm or corporate law department of over 25
lawyers or was a judge of a court of general jurisdiction. The arbitrator shall
issue an award no more than three months after selection of the arbitrator.

     The venue and the governing law shall be in and that of San Diego,
California and the State of California, without giving effect to conflict of law
considerations, or Seattle, Washington and the State of Washington, without
giving effect to conflict of law considerations, at the instance of the Party
which is the respondent in the first notice of intent to arbitrate. In no event
shall punitive or exemplary damages, pre-judgment interest, or attorney's fees
be awardable.

     Notwithstanding the foregoing dispute resolution and governing law
provisions, PRI and Dendreon shall each retain the right to seek judicial
injunctive and other equitable relief where appropriate.

     In Witness Whereof, the Parties have caused this Agreement to be executed
as of the Effective Date.

The R.W. Johnson Pharmaceutical          Dendreon Corporation
Research Institute, a division of
Ortho-McNeil Pharmaceutical, Inc.

By: /s/ Per A. Peterson                  By: /s/ David L. Urdal
    ------------------------------           --------------------------------

Name: Per A. Peterson, M.D., Ph.D.       Name: David L. Urdal, Ph.D.
      ----------------------------             ------------------------------

Title: President                         Title: Executive Vice President
       ---------------------------              -----------------------------

Date: October 6, 2000                 Date: October 5, 2000
             ---                                   ---

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                      12.
<PAGE>

                                  Schedule A

            RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE (PRI) AND
                        DENDREON CORPORATION (DENDREON)
                          COLLABORATION RESEARCH PLAN

                                     [ * ]

                       (Five pages of text omitted here)

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                     A-1.
<PAGE>

                                 Schedule B-1

                               DENDREON PATENTS

                                     [ * ]

                        (Five page chart omitted here)

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                     B1-1.
<PAGE>

                                 Schedule B-2

                                  PRI PATENTS

                                     [ * ]

                         (One page chart omitted here)

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                     B2-1.
<PAGE>

                                  Schedule C

The following publicity and disclosures are approved:

1.   Statement for filing with the U.S. Securities and Exchange Commission in
     substantially the form and content attached.

2.   Press release in substantially the form and content attached.

3.   Reference in Dendreon's web site to this Agreement in substantially the
     content of the SEC statement referred to in 1 above and the press release
     referenced to in 2 above.

4.   Reference in Dendreon's company fact sheets to this Agreement in
     substantially the content of the SEC statement referred to in 1 above and
     the press release referred to in 2 above.

5.   Oral and graphic reference in industry and professional presentations and
     presentations and communications with investors, potential investors and
     analysts to this Agreement in substantially the content of the SEC
     statement referred to in 1 above and the press release referenced to in 2
     above.

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                      1.
<PAGE>

                                 SEC STATEMENT

                                                              September 29, 2000

     On October ____, 2000 we entered into a Research Collaboration And License
Agreement with The R.W. Johnson Pharmaceutical Institute (PRI), a division of
Ortho-McNeil Pharmaceutical, Inc.

     The agreement provides for studies of PRI technology and of our technology
to determine their respective feasibility as immunotherapy products for the
treatment of a variety of cancers, including breast, ovarian, and colorectal
cancers. The research plan, covering a defined territory and field, will be
performed jointly by Dendreon and PRI. It will involve at least two Phase I
clinical trials of human subjects performed by Dendreon.

     Under the agreement, PRI will pay us a study fee and a milestone payment at
the initiation of clinical trials under our Investigational New Drug
application, to be filed with the U.S. Food and Drug Administration, for
APC8024, our proprietary antigen activated dendritic cell product. The agreement
also provides in part that PRI will fund the research plan by paying us for our
research effort. PRI will receive exclusive access to the work and its results
and an exclusive right to negotiate with us during the term of the agreement
regarding further activities in the territory and field covered by the
agreement.

     The agreement provides that during the course of this collaboration, PRI
and we will endeavor to agree upon terms for future collaboration using PRI's
and our respective separate and/or combined technologies.

     Work under the agreement is scheduled to begin in 2000.

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                      2.
<PAGE>

Julie Rathbun
Communications/Investor Relations
(206) 256-4545 ext. 1500
jrathbun@dendreon.com

Dendreon Announces Collaboration with The R.W. Johnson Pharmaceutical Research
Institute in Development of Immunotherapy for Cancer

-  leader in cancer vaccines to advance research and development activities

Seattle, WA (October     2000) - Dendreon Corporation (Nasdaq: DNDN) today
announced the signing of a strategic collaboration agreement for the advancement
of cancer immunotherapies with The R.W. Johnson Pharmaceutical Research
Institute (PRI), a member of the Johnson & Johnson family of companies (NYSE:
JNJ).

The Collaboration will provide the opportunity for Dendreon and PRI to pool
products and technologies to develop optimal immunotherapies, including
dendritic cell-based vaccine therapy for the treatment of a variety of cancers,
including breast, ovarian and colorectal cancers. The collaboration will also
involve a pooling of products and technologies which may be developed by the
companies.

"PRI is a strong partner for Dendreon Corporation," said David Urdal, Ph.D.,
Chief Scientific Officer of Dendreon. "PRI's innovation in biotechnology,
coupled with Dendreon's leadership in the cancer immunotherapy arena, provides a
significant validation for this important area of clinical development and a
strong groundwork for our future research and development activities."

Under the terms of the agreement, PRI will provide financial support for
research and development activities to be carried out by Dendreon. Dendreon will
also be responsible for clinical testing.

Immunotherapy treatments aim to harness the natural power of the immune system
to fight against diseases such as cancer. Avoiding the harsh side effects
associated with other forms of treatment, immunotherapies may offer new hope to
patients.

Dendreon Corporation (www.dendreon.com) is dedicated to the discovery and
development of novel products for the treatment of cancer through its innovative
manipulation of the immune system. Dendreon is focused on the development of
therapeutic cancer vaccines through the use of antigen discovery, antigen
engineering and dendritic cell technologies. Dendreon's vaccine for the
treatment of prostate cancer, Provenge(TM), is in Phase III clinical trials and
its vaccine for the treatment of multiple myeloma, Mylovenge(TM), is in Phase II
clinical trials.

Except for historical information contained herein, this news release contains
forward-looking statements that are subject to risks and uncertainties that may
cause actual results to differ materially from the results discussed in the
forward-looking statements, particularly those inherent in the process of
discovering, developing and commercializing drugs that are safe and effective
for use as human therapeutics. Factors that may cause such a difference include
risks

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                      3.
<PAGE>

related to Dendreon's limited operating history, risks associated with
completing our clinical trials, and dependence on the efforts of third parties,
and our dependence on intellectual property. Further information on the factors
and risks that could affect Dendreon's business, financial condition and results
of operations, are contained in Dendreon's SEC Reports, including Dendreon's
Form 10-Q and Form S-1 Registration Statement, No. 333-31920, which are
available at www.sec.gov.

                                     # # #

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                      4.<PAGE>

                                                                     EXHIBIT 4.3

                               ABSOLUTEFUTURE.COM

                 AMENDED AND RESTATED 1999 STOCK INCENTIVE PLAN

                              SECTION 1.  PURPOSE
                              -------------------

     The purpose of the Absolutefuture.com Amended and Restated 1999 Stock
Incentive Plan (the "Plan") is to enhance the long-term shareholder value of
Absolutefuture.com, a Nevada corporation (the "Company"), by offering
opportunities to selected persons to participate in the Company's growth and
success, and to encourage them to remain in the service of the Company and its
Related Corporations (as defined in Section 2) and to acquire and maintain stock
ownership in the Company.

                            SECTION 2.  DEFINITIONS
                            -----------------------

     For purposes of the Plan, the following terms shall be defined as set forth
below:

     "Award" means an award or grant made pursuant to the Plan, including,
without limitation, awards or grants of Stock Awards and Options, or any
combination of the foregoing.

     "Board" means the Board of Directors of the Company.

     "Cause," unless otherwise defined in an employment or services agreement
between the Company or a Related Corporation and a Participant, means
dishonesty, fraud, misconduct, unauthorized use or disclosure of confidential
information or trade secrets, or conviction or confession of a crime punishable
by law (except minor violations), in each case as determined by the Plan
Administrator, and its determination shall be conclusive and binding.

     "Code" means the Internal Revenue Code of 1986, as amended from time to
time.

     "Common Stock" means the common stock, par value $0.001 per share, of the
Company.

     "Corporate Transaction" has the meaning set forth in Section 12.3.1.

     "Disability," unless otherwise defined by the Plan Administrator, means a
mental or physical impairment of the Participant that is expected to result in
death or that has lasted or is expected to last for a continuous period of 12
months or more and that causes the Participant to be unable, in the opinion of
the Company, to perform his or her duties for the Company or a Related
Corporation and to be engaged in any substantial gainful activity.

     "Effective Date" has the meaning set forth in Section 16.

     "Exchange Act" means the Securities Exchange Act of 1934, as amended.

     "Fair Market Value" shall be as established in good faith by the Plan
Administrator or (a) if the Common Stock is listed on the Nasdaq National
Market, the average of the high and low per share sales prices for the Common
Stock as reported by the Nasdaq National Market for a single trading day or (b)
if the Common Stock is listed on the New York Stock Exchange or the American
Stock Exchange, the average of the high and low per share sales prices for the
Common Stock as such price is officially quoted in the composite tape of
transactions on such exchange for a single trading day.  If the Common Stock is
not listed on the Nasdaq National Market, the New York Stock Exchange or the
American Stock Exchange and the Common Stock is listed on the NASD OTC Bulletin
Board, then the average of the high and low per share sales prices for the
Common Stock as reported by the NASD OTC Bulletin Board for a single trading
day.  If there is no such reported price for the Common Stock for the date in
question, then such price on the last preceding date for which such price exists
shall be determinative of Fair Market Value.

                                                                    Page 8 of 29
<PAGE>

     "Good Reason" means the occurrence of any of the following events or
conditions and the failure of the Successor Corporation to cure such event or
condition within 30 days after receipt of written notice from the Participant:

     (a) a change in the Participant's status, title, position or
responsibilities (including reporting responsibilities) that, in the
Participant's reasonable judgment, represents a substantial reduction in the
status, title, position or responsibilities as in effect immediately prior
thereto; the assignment to the Participant of any duties or responsibilities
that, in the Participant's reasonable judgment, are materially inconsistent with
such status, title, position or responsibilities; or any removal of the
Participant from or failure to reappoint or reelect the Participant to any of
such positions, except in connection with the termination of the Participant's
employment for Cause, for Disability or as a result of his or her death, or by
the Participant other than for Good Reason;

     (b) a reduction in the Participant's annual base salary;

     (c) the Successor Corporation's requiring the Participant (without the
Participant's consent) to be based at any place outside a 35-mile radius of his
or her place of employment prior to a Corporate Transaction, except for
reasonably required travel on the Successor Corporation's business that is not
materially greater than such travel requirements prior to the Corporate
Transaction;

     (d) the Successor Corporation's failure to (i) continue in effect any
material compensation or benefit plan (or the substantial equivalent thereof) in
which the Participant was participating at the time of a Corporate Transaction,
including, but not limited to, the Plan, or (ii) provide the Participant with
compensation and benefits substantially equivalent (in terms of benefit levels
and/or reward opportunities) to those provided for under each material employee
benefit plan, program and practice as in effect immediately prior to the
Corporate Transaction;

     (e) any material breach by the Successor Corporation of its obligations to
the Participant under the Plan or any substantially equivalent plan of the
Successor Corporation; or

     (f) any purported termination of the Participant's employment or service
relationship for Cause by the Successor Corporation that is not in accordance
with the definition of Cause under the Plan.

     "Grant Date" means the date on which the Plan Administrator completes the
corporate action relating to the grant of an Award and all conditions precedent
to the grant have been satisfied, provided that conditions to the exercisability
or vesting of Awards shall not defer the Grant Date.

     "Incentive Stock Option" means an Option to purchase Common Stock granted
under Section 7 with the intention that it qualify as an "incentive stock
option" as that term is defined in Section 422 of the Code.

     "Nonqualified Stock Option" means an Option to purchase Common Stock
granted under Section 7 other than an Incentive Stock Option.

     "Option" means the right to purchase Common Stock granted under Section 7.

     "Option Term" has the meaning set forth in Section 7.3.

     "Parent," except as otherwise provided in Section 8 in connection with
Incentive Stock Options, means any entity, whether now or hereafter existing,
that directly or indirectly controls the Company.

     "Participant" means the person to whom an Award is granted.

     "Plan Administrator" means the Board or any committee or committees
designated by the Board to administer the Plan under Section 3.1.

     "Related Corporation" means any Parent or Subsidiary of the Company.

                                                                    Page 9 of 29
<PAGE>

     "Related Party Transaction" means (a) a merger of the Company in which the
holders of shares of Common Stock immediately prior to the merger hold at least
a majority of the shares of Common Stock in the surviving corporation
immediately after the merger, (b) a mere reincorporation of the Company or (c) a
transaction undertaken for the sole purpose of creating a holding company.

     "Retirement" means retirement as of the individual's normal retirement date
under the Company's 401(k) plan or other similar successor plan applicable to
salaried employees, unless otherwise defined by the Plan Administrator from time
to time for purposes of the Plan.

     "Securities Act" means the Securities Act of 1933, as amended.

     "Stock Award" means shares of Common Stock or units denominated in Common
Stock granted under Section 9, the rights of ownership of which may be subject
to restrictions prescribed by the Plan Administrator.

     "Subsidiary," except as otherwise provided in Section 8 in connection with
Incentive Stock Options, means any entity that is directly or indirectly
controlled by the Company.

     "Successor Corporation" has the meaning set forth in Section 12.3.

     "Termination Date" has the meaning set forth in Section 7.6.

     "Vesting Commencement Date" means the Grant Date or such other date
selected by the Plan Administrator as the date from which an Option begins to
vest for purposes of Section 7.4.

                           SECTION 3.  ADMINISTRATION
                           --------------------------

3.1  Plan Administrator

     The Plan shall be administered by the Board and/or a committee or
committees (which term includes subcommittees) appointed by, and consisting of
two or more members of, the Board (a "Plan Administrator").  If and so long as
the Common Stock is registered under Section 12(b) or 12(g) of the Exchange Act,
the Board shall consider in selecting the members of any committee acting as
Plan Administrator, with respect to any persons subject or likely to become
subject to Section 16 of the Exchange Act, the provisions regarding (a) "outside
directors" as contemplated by Section 162(m) of the Code and (b) "nonemployee
directors" as contemplated by Rule 16b-3 under the Exchange Act.
Notwithstanding the foregoing, the Board may delegate the responsibility for
administering the Plan with respect to designated classes of eligible persons to
different committees consisting of two or more members of the Board, subject to
such limitations as the Board deems appropriate.  Committee members shall serve
for such term as the Board may determine, subject to removal by the Board at any
time.

3.2  Administration and Interpretation by Plan Administrator

     Except for the terms and conditions explicitly set forth in the Plan, the
Plan Administrator shall have exclusive authority, in its discretion, to
determine all matters relating to Awards under the Plan, including the selection
of individuals to be granted Awards, the type of Awards, the number of shares of
Common Stock subject to an Award, all terms, conditions, restrictions and
limitations, if any, of an Award and the terms of any instrument that evidences
the Award.  The Plan Administrator shall also have exclusive authority to
interpret the Plan and the terms of any instrument evidencing the Award and may
from time to time adopt and change rules and regulations of general application
for the Plan's administration.  The Plan Administrator's interpretation of the
Plan and its rules and regulations, and all actions taken and determinations
made by the Plan Administrator pursuant to the Plan, shall be conclusive and
binding on all parties involved or affected.  The Plan Administrator may
delegate administrative duties to such of the Company's officers as it so
determines.

                                                                   Page 10 of 29
<PAGE>

                     SECTION 4.  STOCK SUBJECT TO THE PLAN
                     -------------------------------------

4.1  Authorized Number of Shares

     Subject to adjustment from time to time as provided in Section 12.1, a
maximum of 3,000,000 shares of Common Stock shall be available for issuance
under the Plan.

     Shares issued under the Plan shall be drawn from authorized and unissued
shares or shares now held or subsequently acquired by the Company

4.2  Limitations

     (a) Subject to adjustment from time to time as provided in Section 12.1,
not more than an aggregate of 300,000 shares shall be available for issuance
pursuant to grants of Stock Awards under the Plan.

     (b) Subject to adjustment from time to time as provided in Section 12.1,
not more than 100,000 shares of Common Stock may be made subject to Awards under
the Plan to any individual in the aggregate in any one fiscal year of the
Company, except that the Company may make additional one-time grants of up to
500,000 shares to newly hired individuals, such limitation to be applied in a
manner consistent with the requirements of, and only to the extent required for
compliance with, the exclusion from the limitation on deductibility of
compensation under Section 162(m) of the Code.

4.3  Reuse of Shares

     Any shares of Common Stock that have been made subject to an Award that
cease to be subject to the Award (other than by reason of exercise or payment of
the Award to the extent it is exercised for or settled in shares) shall again be
available for issuance in connection with future grants of Awards under the
Plan; provided, however, that for purposes of Section 4.2, any such shares shall
be counted in accordance with the requirements of Section 162(m) of the Code.

                            SECTION 5.  ELIGIBILITY
                            -----------------------

    Awards may be granted under the Plan to those officers, directors and
employees of the Company and its Related Corporations as the Plan Administrator
from time to time selects.  Awards may also be made to consultants, agents,
advisors and independent contractors who provide services to the Company and its
Related Corporations, so long as such Participants (a) are natural persons or
alter ego entities of the natural persons providing the services; (b) render
bona fide services that are not in connection with the offer and sale of the
Company's securities in a capital-raising transaction; and (c) do not directly
or indirectly promote or maintain a market for the Company's securities.

                               SECTION 6.  AWARDS
                               ------------------

6.1  Form and Grant of Awards

     The Plan Administrator shall have the authority, in its sole discretion, to
determine the type or types of Awards to be made under the Plan.  Such Awards
may include, but are not limited to, Incentive Stock Options, Nonqualified Stock
Options and Stock Awards.  Awards may be granted singly or in combination.

6.2  Settlement of Awards

     The Company may settle Awards through the delivery of shares of Common
Stock, the granting of replacement Awards or any combination thereof as the Plan
Administrator shall determine.  Any Award settlement, including payment
deferrals, may be subject to such conditions, restrictions and contingencies as
the Plan

                                                                   Page 11 of 29
<PAGE>

Administrator shall determine. The Plan Administrator may permit or require the
deferral of any Award payment, subject to such rules and procedures as it may
establish, which may include provisions for the payment or crediting of
interest, or dividend equivalents, including converting such credits into
deferred stock equivalents.

6.3  Acquired Company Awards

     Notwithstanding anything in the Plan to the contrary, the Plan
Administrator may grant Awards under the Plan in substitution for awards issued
under other plans, or assume under the Plan awards issued under other plans, if
the other plans are or were plans of other acquired entities ("Acquired
Entities") (or the parent of the Acquired Entity) and the new Award is
substituted, or the old award is assumed, by reason of a merger, consolidation,
acquisition of property or stock, reorganization or liquidation (the
"Acquisition Transaction").  In the event that a written agreement pursuant to
which the Acquisition Transaction is completed is approved by the Board and said
agreement sets forth the terms and conditions of the substitution for or
assumption of outstanding awards of the Acquired Entity, said terms and
conditions shall be deemed to be the action of the Plan Administrator without
any further action by the Plan Administrator, except as may be required for
compliance with Rule 16b-3 under the Exchange Act, and the persons holding such
awards shall be deemed to be Participants.

                         SECTION 7.  AWARDS OF OPTIONS
                         -----------------------------

7.1  Grant of Options

     The Plan Administrator is authorized under the Plan, in its sole
discretion, to issue Options as Incentive Stock Options or as Nonqualified Stock
Options, which shall be appropriately designated.

7.2  Option Exercise Price

     The exercise price for shares purchased under an Option shall be as
determined by the Plan Administrator, but shall not be less than 100% of the
Fair Market Value of the Common Stock on the Grant Date with respect to
Incentive Stock Options.  For Incentive Stock Options granted to a more than 10%
shareholder, the Option exercise price shall be as specified in Section 8.2.

7.3  Term of Options

     The term of each Option (the "Option Term") shall be as established by the
Plan Administrator or, if not so established, shall be ten years from the Grant
Date.  For Incentive Stock Options, the maximum Option Term shall be as
specified in Sections 8.2 and 8.4.

7.4  Exercise of Options

     The Plan Administrator shall establish and set forth in each instrument
that evidences an Option the time at which, or the installments in which, the
Option shall vest and become exercisable, which provisions may be waived or
modified by the Plan Administrator at any time.  If not so established in the
instrument evidencing the Option, the Option shall vest and become exercisable
according to the following schedule, which may be waived or modified by the Plan
Administrator at any time:

 Period of Participant's Continuous
 Employment or Service With the Company
 or Its Related Corporations From the
 Vesting Commencement Date                    Percent of Total Option
                                              That Is Vested and Exercisable

 After 4 months of fulltime employment        25%
                                                                   Page 12 of 29
<PAGE>

 Each additional one-month period of       An additional 1/20
 continuous employment completed
 thereafter

 After 2 years                             100%

     The Plan Administrator may adjust the vesting schedule of an Option held by
a Participant who works less than "full-time" as that term is defined by the
Plan Administrator or who takes a Company-approved leave of absence.

     To the extent that an Option has vested and become exercisable, the Option
may be exercised from time to time by delivery to the Company of a written stock
option exercise agreement or notice, in a form and in accordance with procedures
established by the Plan Administrator, setting forth the number of shares with
respect to which the Option is being exercised, the restrictions imposed on the
shares purchased under such exercise agreement, if any, and such representations
and agreements as may be required by the Plan Administrator, accompanied by
payment in full as described in Section 7.5.  An Option may be exercised only
for whole shares and may not be exercised for less than a reasonable number of
shares at any one time, as determined by the Plan Administrator.

7.5  Payment of Exercise Price

     The exercise price for shares purchased under an Option shall be paid in
full to the Company by delivery of consideration equal to the product of the
Option exercise price and the number of shares purchased.  Such consideration
must be paid before the Company will issue the shares being purchased and must
be in a form or a combination of forms acceptable to the Plan Administrator for
that purchase, which forms may include:

     (a)  cash;

     (b)  check;

     (c)  tendering (either actually or, if the Common Stock is registered under
Section 12(b) or 12(g) of the Exchange Act, by attestation) shares of Common
Stock already owned by the Participant for at least six months (or any shorter
period necessary to avoid a charge to the Company's earnings for financial
reporting purposes) that on the day prior to the exercise date have a Fair
Market Value equal to the aggregate exercise price of the shares being purchased
under the Option;

     (d)  if the Common Stock is registered under Section 12(b) or 12(g) of the
Exchange Act, delivery of a properly executed exercise notice, together with
irrevocable instructions to a brokerage firm designated by the Company to
deliver promptly to the Company the aggregate amount of sale or loan proceeds to
pay the Option exercise price and any withholding tax obligations that may arise
in connection with the exercise, all in accordance with the regulations of the
Federal Reserve Board; or

     (e)  such other consideration as the Plan Administrator may permit.

     In addition, to assist a Participant (including a Participant who is an
officer or a director of the Company) in acquiring shares of Common Stock
pursuant to an Award granted under the Plan, the Plan Administrator, in its sole
discretion, may authorize, either at the Grant Date or at any time before the
acquisition of Common Stock pursuant to the Award, (i) the payment by a
Participant of the purchase price of the Common Stock by a full-recourse
promissory note or  (ii) the guarantee by the Company of a full-recourse loan
obtained by the Participant from a third party.  Subject to the foregoing, the
Plan Administrator shall in its sole discretion specify the terms of any loans
or loan guarantees, including the interest rate and terms of and security for
repayment.

7.6  Post-Termination Exercises

     The Plan Administrator shall establish and set forth in each instrument
that evidences an Option whether the Option shall continue to be exercisable,
and the terms and conditions of such exercise, if a Participant ceases to

                                                                   Page 13 of 29
<PAGE>

be employed by, or to provide services to, the Company or its Related
Corporations, which provisions may be waived or modified by the Plan
Administrator at any time. If not so established in the instrument evidencing
the Option, the Option shall be exercisable according to the following terms and
conditions, which may be waived or modified by the Plan Administrator at any
time:

     (a) Any portion of an Option that is not vested and exercisable on the date
of termination of the Participant's employment or service relationship (the
"Termination Date") shall expire on such date.

     (b) Any portion of an Option that is vested and exercisable on the
Termination Date shall expire upon the earliest to occur of

         (i)   the last day of the Option Term;

         (ii)  if the Participant's Termination Date occurs for reasons other
than Cause, death, Disability, or Retirement, the three-month anniversary of
such Termination Date; and

         (iii) if the Participant's Termination Date occurs by reason of death,
Disability, or Retirement, the one-year anniversary of such Termination Date.

     Notwithstanding the foregoing, if the Participant dies after the
Termination Date while the Option is otherwise exercisable, the portion of the
Option that is vested and exercisable on such Termination Date shall expire upon
the earlier to occur of (y) the last day of the Option Term and (z) the first
anniversary of the date of death, unless the Plan Administrator determines
otherwise.

     Also notwithstanding the foregoing, in case of termination of the
Participant's employment or service relationship for Cause, the Option shall
automatically expire upon first notification to the Participant of such
termination, unless the Plan Administrator determines otherwise.  If a
Participant's employment or service relationship with the Company is suspended
pending an investigation of whether the Participant shall be terminated for
Cause, all the Participant's rights under any Option likewise shall be suspended
during the period of investigation.

     (c) A Participant's transfer of employment or service relationship between
or among the Company and its Related Corporations, or a change in status from an
employee to a consultant, agent, advisor or independent contractor or a change
in status from a consultant, agent, advisor or independent contractor to an
employee, shall not be considered a termination of employment or service
relationship for purposes of this Section 7.

     (d) The effect of a Company-approved leave of absence on the terms and
conditions of an Option shall be determined by the Plan Administrator, in its
sole discretion.

                 SECTION 8.  INCENTIVE STOCK OPTION LIMITATIONS
                 ----------------------------------------------

     To the extent required by Section 422 of the Code, Incentive Stock Options
shall be subject to the following additional terms and conditions:

8.1  Dollar Limitation

     To the extent the aggregate Fair Market Value (determined as of the Grant
Date) of Common Stock with respect to which Incentive Stock Options are
exercisable for the first time during any calendar year (under the Plan and all
other stock option plans of the Company) exceeds $100,000, such portion in
excess of $100,000 shall be treated as a Nonqualified Stock Option.  In the
event the Participant holds two or more such Options that become exercisable for
the first time in the same calendar year, such limitation shall be applied on
the basis of the order in which such Options are granted.

                                                                   Page 14 of 29
<PAGE>

8.2  More Than 10% Shareholders

     If an individual owns more than 10% of the total combined voting power of
all classes of stock of the Company or of its parent or subsidiary corporations,
then the exercise price per share of an Incentive Stock Option shall not be less
than 110% of the Fair Market Value of the Common Stock on the Grant Date and the
Option Term shall not exceed five years.  The determination of more than 10%
ownership shall be made in accordance with Section 422 of the Code.

8.3  Eligible Employees

     Individuals who are not employees of the Company or one of its parent
corporations or subsidiary corporations may not be granted Incentive Stock
Options.

8.4  Term

     Except as provided in Section 8.2, the Option Term shall not exceed 10
years.

8.5  Exercisability

     An Option designated as an Incentive Stock Option shall cease to qualify
for favorable tax treatment as an Incentive Stock Option to the extent it is
exercised (if permitted by the terms of the Option) (a) more than three months
after the Termination Date for reasons other than death or Disability, (b) more
than one year after the Termination Date by reason of Disability, or (c) after
the Participant has been on leave of absence for more than 90 days, unless the
Participant's reemployment rights are guaranteed by statute or contract.

8.6  Taxation of Incentive Stock Options

     In order to obtain certain tax benefits afforded to Incentive Stock Options
under Section 422 of the Code, the Participant must hold the shares issued upon
the exercise of an Incentive Stock Option for two years after the Grant Date and
one year from the date of exercise.  A Participant may be subject to the
alternative minimum tax at the time of exercise of an Incentive Stock Option.
The Participant shall give the Company prompt notice of any disposition of
shares acquired by the exercise of an Incentive Stock Option prior to the
expiration of such holding periods.

8.7  Promissory Notes

     The amount of any promissory note delivered pursuant to Section 7.5 in
connection with an Incentive Stock Option shall bear interest at a rate
specified by the Plan Administrator, but in no case less than the rate required
to avoid imputation of interest (taking into account any exceptions to the
imputed interest rules) for federal income tax purposes.

8.8  Code Definitions

     For purposes of this Section 8, "parent corporation," "subsidiary
corporation" and "Disability" shall have the meanings attributed to those terms
for purposes of Section 422 of the Code.

                            SECTION 9.  STOCK AWARDS
                            ------------------------

9.1  Grant of Stock Awards

     The Plan Administrator is authorized to make Awards of Common Stock or
Awards denominated in units of Common Stock on such terms and conditions and
subject to such restrictions, if any (which may be based on

                                                                   Page 15 of 29
<PAGE>

continuous service with the Company or the achievement of performance goals
related to profits, profit growth, profit-related return ratios, cash flow or
total shareholder return, where such goals may be stated in absolute terms or
relative to comparison companies), as the Plan Administrator shall determine, in
its sole discretion, which terms, conditions and restrictions shall be set forth
in the instrument evidencing the Award. The terms, conditions and restrictions
that the Plan Administrator shall have the power to determine shall include,
without limitation, the manner in which shares subject to Stock Awards are held
during the periods they are subject to restrictions and the circumstances under
which forfeiture of the Stock Award shall occur by reason of termination of the
Participant's employment or service relationship.

9.2  Issuance of Shares

     Upon the satisfaction of any terms, conditions and restrictions prescribed
in respect to a Stock Award, or upon the Participant's release from any terms,
conditions and restrictions of a Stock Award, as determined by the Plan
Administrator, the Company shall release, as soon as practicable, to the
Participant or, in the case of the Participant's death, to the personal
representative of the Participant's estate or as the appropriate court directs,
the appropriate number of shares of Common Stock.

9.3  Waiver of Restrictions

     Notwithstanding any other provisions of the Plan, the Plan Administrator
may, in its sole discretion, waive the forfeiture period and any other terms,
conditions or restrictions on any Stock Award under such circumstances and
subject to such terms and conditions as the Plan Administrator shall deem
appropriate provisions; provided, however, that the Plan Administrator may not
adjust performance goals for any Stock Award intended to be exempt under Section
162(m) of the Code for the year in which the Stock Award is settled in such a
manner as would increase the amount of compensation otherwise payable to a
Participant.

                           SECTION 10. WITHHOLDING
                           -----------------------

     The Company may require the Participant to pay to the Company the amount of
any withholding taxes that the Company is required to withhold with respect to
the grant, vesting or exercise of any Award. Subject to the Plan and applicable
law, the Plan Administrator may, in its sole discretion, permit the Participant
to satisfy withholding obligations , in whole or in part, (a) by paying cash,
(b) by electing to have the Company withhold shares of Common Stock having a
value equal to the tax withholding obligations (up to the employer's minimum
required tax withholding rate) or (c) by transferring to the Company shares of
Common Stock having a value equal to the tax withholding obligations (up to the
employer's minimum required tax withholding rate to the extent the Participant
has held the transferred shares for less than six months). The Company shall
have the right to withhold from any Award or any shares of Common Stock issuable
pursuant to an Award or from any cash amounts otherwise due or to become due
from the Company to the Participant an amount equal to such taxes.

                          SECTION 11. ASSIGNABILITY
                          -------------------------

     Awards granted under the Plan and any interest therein may not be assigned,
pledged or transferred by the Participant and may not be made subject to
attachment or similar proceedings otherwise than by will or by the applicable
laws of descent and distribution, and, during the Participant's lifetime, such
Awards may be exercised only by the Participant. Notwithstanding the foregoing,
and to the extent permitted by Section 422 of the Code, the Plan Administrator,
in its sole discretion, may permit such assignment, transfer and exercisability
and may permit a Participant to designate a beneficiary who may exercise the
Award or receive compensation under the Award after the Participant's death;
provided, however, that any Award so assigned or transferred shall be subject to
all the same terms and conditions contained in the instrument evidencing the
Award.

                                                                   Page 16 of 29
<PAGE>

                           SECTION 12. ADJUSTMENTS
                           -----------------------

12.1 Adjustment of Shares

     In the event that, at any time or from time to time, a stock dividend,
stock split, spin-off, combination or exchange of shares, recapitalization,
merger, consolidation, distribution to shareholders other than a normal cash
dividend, or other change in the Company's corporate or capital structure
results in (a) the outstanding shares, or any securities exchanged therefor or
received in their place, being exchanged for a different number or class of
securities of the Company or of any other corporation or (b) new, different or
additional securities of the Company or of any other corporation being received
by the holders of shares of Common Stock of the Company, then the Plan
Administrator shall make proportional adjustments in (i) the maximum number and
kind of securities subject to the Plan as set forth in Section 4.1 and the
maximum number and kind of securities that may be made subject to Stock Awards
and to Awards to any individual as set forth in Section 4.2, and (ii) the number
and kind of securities that are subject to any outstanding Award and the per
share price of such securities, without any change in the aggregate price to be
paid therefor. The determination by the Plan Administrator as to the terms of
any of the foregoing adjustments shall be conclusive and binding.
Notwithstanding the foregoing, a dissolution or liquidation of the Company or a
Corporate Transaction shall not be governed by this Section 12.1 but shall be
governed by Sections 12.2 and 12.3, respectively.

12.2 Dissolution or Liquidation

     In the event of the proposed dissolution or liquidation of the Company, the
Plan Administrator shall notify each Participant as soon as practicable prior to
the effective date of such proposed transaction. The Plan Administrator in its
discretion may permit a Participant to exercise an Option until ten days prior
to such transaction with respect to all vested and exercisable shares of Common
Stock covered thereby and with respect to such number of unvested shares as the
Plan Administrator shall determine. In addition, the Plan Administrator may
provide that any forfeiture provision or Company repurchase option applicable to
any Award shall lapse as to such number of shares as the Plan Administrator
shall determine, contingent upon the occurrence of the proposed dissolution or
liquidation at the time and in the manner contemplated. To the extent an Option
has not been previously exercised, the Option shall terminate automatically
immediately prior to the consummation of the proposed action. To the extent a
forfeiture provision applicable to a Stock Award has not been waived by the Plan
Administrator, the Stock Award shall be forfeited automatically immediately
prior to the consummation of the proposed action.

12.3 Corporate Transaction

    12.3.1  Definitions

     The following terms shall be defined as set forth below:

     "Corporate Transaction" means any of the following events:

     (a)  Consummation of any merger or consolidation of the Company with or
into another corporation; or

     (b)  Consummation of any sale, lease, exchange or other transfer in one
transaction or a series of related transactions of all or substantially all the
Company's outstanding securities or substantially all the Company's assets other
than a transfer of the Company's assets to a majority-owned subsidiary
corporation (as defined in Section 8) of the Company; or

     (c)  Acquisition by a person, within the meaning of Section 3(a)(9) or of
Section 13(d)(3) (as in effect on the date of adoption of the Plan) of the
Exchange Act of a majority or more of the Company's outstanding voting
securities (whether directly or indirectly, beneficially or of record).
Ownership of voting securities shall take into account and shall include
ownership as determined by applying Rule 13d-3(d)(1)(i) (as in effect on the
date of adoption of the Plan) under the Exchange Act.

                                                                   Page 17 of 29
<PAGE>

    12.3.2  Options

     In the event of a Corporate Transaction, except as otherwise provided in
the instrument evidencing the Award, each outstanding Option shall be assumed or
continued or an equivalent option or right substituted by the surviving
corporation, the successor corporation or its parent corporation, as applicable
(the "Successor Corporation"). In the event that the Successor Corporation
refuses to assume, continue or substitute for the Option, the Participant shall
fully vest in and have the right to exercise the Option as to all of the shares
of Common Stock subject thereto, including shares as to which the Option would
not otherwise be vested or exercisable. If an Option will become fully vested
and exercisable in lieu of assumption or substitution in the event of a
Corporate Transaction, the Plan Administrator shall notify the Participant in
writing or electronically that the Option shall be fully vested and exercisable
for a specified time period after the date of such notice, and the Option shall
terminate upon the expiration of such period, in each case conditioned on the
consummation of the Corporate Transaction. For the purposes of this Section
12.3, the Option shall be considered assumed if, following the Corporate
Transaction, the option or right confers the right to purchase or receive, for
each share of Common Stock subject to the Option, immediately prior to the
Corporate Transaction, the consideration (whether stock, cash, or other
securities or property) received in the merger or sale of assets by holders of
Common Stock for each share held on the effective date of the transaction (and
if holders were offered a choice of consideration, the type of consideration
chosen by the holders of a majority of the outstanding shares); provided,
however, that if such consideration received in the Corporate Transaction is not
solely common stock of the Successor Corporation, the Plan Administrator may,
with the consent of the Successor Corporation, provide for the consideration to
be received upon the exercise of the Option, for each share of Common Stock
subject thereto, to be solely common stock of the Successor Corporation equal in
fair market value to the per share consideration received by holders of Common
Stock in the Corporate Transaction. All Options shall terminate and cease to
remain outstanding immediately following the consummation of the Corporate
Transaction, except to the extent assumed by the Successor Corporation.

    12.3.3  Stock Awards

     In the event of a Corporate Transaction, the vesting of shares subject to
Stock Awards shall accelerate, and the forfeiture provisions to which such
shares are subject shall lapse, if and to the same extent that the vesting of
outstanding Options accelerates in connection with the Corporate Transaction. If
unvested Options are to be assumed, continued or substituted by a Successor
Corporation without acceleration upon the occurrence of a Corporate Transaction,
the forfeiture provisions to which such Stock Awards are subject will continue
with respect to shares of the Successor Corporation that may be issued in
exchange for such shares.

    12.3.4  Acceleration Following a Corporate Transaction

     Any Awards that are assumed, continued or replaced in the Corporate
Transaction, other than a Related Party Transaction, and do not otherwise
accelerate at that time shall be accelerated in the event that the Participant's
employment or service relationship should subsequently terminate within two
years following such Corporate Transaction, unless such employment or service
relationship is terminated by the Successor Corporation for Cause or by the
Participant voluntarily without Good Reason.

12.4 Further Adjustment of Awards

     Subject to Sections 12.2 and 12.3, the Plan Administrator shall have the
discretion, exercisable at any time before a sale, merger, consolidation,
reorganization, liquidation or change in control of the Company, as defined by
the Plan Administrator, to take such further action as it determines to be
necessary or advisable, and fair and equitable to the Participants, with respect
to Awards. Such authorized action may include (but shall not be limited to)
establishing, amending or waiving the type, terms, conditions or duration of, or
restrictions on, Awards so as to provide for earlier, later, extended or
additional time for exercise, lifting restrictions and other modifications, and
the Plan Administrator may take such actions with respect to all Participants,
to certain categories of Participants or only to individual Participants. The
Plan Administrator may take such action before or after granting Awards to which
the action relates and before or after any public announcement with respect to
such sale, merger, consolidation, reorganization, liquidation or change in
control that is the reason for such action.

                                                                   Page 18 of 29
<PAGE>

12.5 Limitations

     The grant of Awards shall in no way affect the Company's right to adjust,
reclassify, reorganize or otherwise change its capital or business structure or
to merge, consolidate, dissolve, liquidate or sell or transfer all or any part
of its business or assets.

                         SECTION 13. MARKET STANDOFF
                         ---------------------------

     In connection with any underwritten public offering by the Company of its
equity securities pursuant to an effective registration statement filed under
the Securities Act, a person shall not sell, make any short sale of, loan,
hypothecate, pledge, grant any option for the purchase of, or otherwise dispose
of or transfer for value or otherwise agree to engage in any of the foregoing
transactions with respect to any shares issued pursuant to an Award granted
under the Plan without the prior written consent of the Company or its
underwriters. Such limitations shall be in effect for such period of time as may
be requested by the Company or such underwriters and agreed to by the Company's
officers and directors with respect to their shares; provided, however, that in
no event shall such period exceed 180 days. The limitations of this paragraph
shall in all events terminate two years after the effective date of the
Company's initial public offering. Holders of shares issued pursuant to an Award
granted under the Plan shall be subject to the market standoff provisions of
this paragraph only if the officers and directors of the Company are also
subject to similar arrangements.

     In the event of any stock split, stock dividend, recapitalization,
combination of shares, exchange of shares or other change affecting the
Company's outstanding Common Stock effected as a class without the Company's
receipt of consideration, any new, substituted or additional securities
distributed with respect to the purchased shares shall be immediately subject to
the provisions of this Section 13, to the same extent the purchased shares are
at such time covered by such provisions.

     In order to enforce the limitations of this Section 13, the Company may
impose stop-transfer instructions with respect to the purchased shares until the
end of the applicable standoff period.

                 SECTION 14. AMENDMENT AND TERMINATION OF PLAN
                 ---------------------------------------------

14.1 Amendment of Plan

     The Plan may be amended only by the Board in such respects as it shall deem
advisable; provided, however, that to the extent required for compliance with
Section 422 of the Code or any applicable law or regulation, shareholder
approval shall be required for any amendment that would (a) increase the total
number of shares available for issuance under the Plan, (b) modify the class of
persons eligible to receive Options, or (c) otherwise require shareholder
approval under any applicable law or regulation. Any amendment made to the Plan
that would constitute a "modification" to Incentive Stock Options outstanding on
the date of such amendment shall not, without the consent of the Participant, be
applicable to such outstanding Incentive Stock Options but shall have
prospective effect only.

14.2 Termination of Plan

     The Board may suspend or terminate the Plan at any time. The Plan shall
have no fixed expiration date; provided, however, that no Incentive Stock
Options may be granted more than ten years after the later of (a) the Plan's
adoption by the Board and (b) the adoption by the Board of any amendment to the
Plan that constitutes the adoption of a new plan for purposes of Section 422 of
the Code.

14.3 Consent of Participant

     The amendment or termination of the Plan or the amendment of an outstanding
Award shall not, without the Participant's consent, impair or diminish any
rights or obligations under any Award theretofore granted to the Participant
under the Plan. Any change or adjustment to an outstanding Incentive Stock
Option shall not, without the consent of the Participant, be made in a manner so
as to constitute a "modification" that would cause such

                                                                   Page 19 of 29
<PAGE>

Incentive Stock Option to fail to continue to qualify as an Incentive Stock
Option. Notwithstanding the foregoing, any adjustments made pursuant to Section
12 shall not be subject to these restrictions.

                              SECTION 15. GENERAL
                              -------------------

15.1 Evidence of Awards

     Awards granted under the Plan shall be evidenced by a written instrument
that shall contain such terms, conditions, limitations and restrictions as the
Plan Administrator shall deem advisable and that are not inconsistent with the
Plan.

15.2 No Individual Rights

     Nothing in the Plan or any Award granted under the Plan shall be deemed to
constitute an employment contract or confer or be deemed to confer on any
Participant any right to continue in the employ of, or to continue any other
relationship with, the Company or any Related Corporation or limit in any way
the right of the Company or any Related Corporation to terminate a Participant's
employment or other relationship at any time, with or without Cause.

15.3 Registration

     Notwithstanding any other provision of the Plan, the Company shall have no
obligation to issue or deliver any shares of Common Stock under the Plan or make
any other distribution of benefits under the Plan unless such issuance, delivery
or distribution would comply with all applicable laws (including, without
limitation, the requirements of the Securities Act), and the applicable
requirements of any securities exchange or similar entity.

     The Company shall be under no obligation to any Participant to register for
offering or resale or to qualify for exemption under the Securities Act, or to
register or qualify under state securities laws, any shares of Common Stock,
security or interest in a security paid or issued under, or created by, the
Plan, or to continue in effect any such registrations or qualifications if made.
The Company may issue certificates for shares with such legends and subject to
such restrictions on transfer and stop-transfer instructions as counsel for the
Company deems necessary or desirable for compliance by the Company with federal
and state securities laws.

     To the extent that the Plan or any instrument evidencing an Award provides
for issuance of stock certificates to reflect the issuance of shares of Common
Stock, the issuance may be effected on a noncertificated basis, to the extent
not prohibited by applicable law or the applicable rules of any stock exchange.

15.4 No Rights as a Shareholder

     No Option or Stock Award denominated in units shall entitle the Participant
to any cash dividend, voting or other right of a shareholder unless and until
the date of issuance under the Plan of the shares that are the subject of such
Award.

15.5 Compliance With Laws and Regulations

     Notwithstanding anything in the Plan to the contrary, the Plan
Administrator, in its sole discretion, may bifurcate the Plan so as to restrict,
limit or condition the use of any provision of the Plan to Participants who are
officers or directors subject to Section 16 of the Exchange Act without so
restricting, limiting or conditioning the Plan with respect to other
Participants. Additionally, in interpreting and applying the provisions of the
Plan, any Option granted as an Incentive Stock Option pursuant to the Plan
shall, to the extent permitted by law, be construed as an "incentive stock
option" within the meaning of Section 422 of the Code.

                                                                   Page 20 of 29
<PAGE>

15.6 Participants in Foreign Countries

     The Plan Administrator shall have the authority to adopt such
modifications, procedures and subplans as may be necessary or desirable to
comply with provisions of the laws of foreign countries in which the Company or
its Related Corporations may operate to assure the viability of the benefits
from Awards granted to Participants employed in such countries and to meet the
objectives of the Plan.

15.7  No Trust or Fund

      The Plan is intended to constitute an "unfunded" plan. Nothing contained
herein shall require the Company to segregate any monies or other property, or
shares of Common Stock, or to create any trusts, or to make any special deposits
for any immediate or deferred amounts payable to any Participant, and no
Participant shall have any rights that are greater than those of a general
unsecured creditor of the Company.

15.8  Severability

      If any provision of the Plan or any Award is determined to be invalid,
illegal or unenforceable in any jurisdiction, or as to any person, or would
disqualify the Plan or any Award under any law deemed applicable by the Plan
Administrator, such provision shall be construed or deemed amended to conform to
applicable laws, or, if it cannot be so construed or deemed amended without, in
the Plan Administrator's determination, materially altering the intent of the
Plan or the Award, such provision shall be stricken as to such jurisdiction,
person or Award, and the remainder of the Plan and any such Award shall remain
in full force and effect.

15.9  Choice of Law

      The Plan and all determinations made and actions taken pursuant hereto, to
the extent not otherwise governed by the laws of the United States, shall be
governed by the laws of the State of Nevada without giving effect to principles
of conflicts of laws.

15.10 Appendix Provisions

      Participants who are residents of the State of California shall be subject
to the additional terms and conditions set forth in Appendix A to the Plan until
such time as the Common Stock becomes a "listed" security under the Securities
Act.

                          SECTION 16. EFFECTIVE DATE
                          --------------------------

      The Effective Date is the date on which the Plan is adopted by the Board,
so long as it is approved by the Company's shareholders at any time within 12
months of such adoption.

      Adopted by the Board on September 26, 2000 and approved by the Company's
shareholders on __________.

                                                                   Page 21 of 29
<PAGE>

                                  APPENDIX A
                           TO THE ABSOLUTEFUTURE.COM
                AMENDED AND RESTATED 1999 STOCK INCENTIVE  PLAN
                        (For California Residents Only)

     This Appendix to the Absolutefuture.com Amended and Restated 1999 Stock
Incentive Plan (the "Plan") shall have application only to Participants who are
residents of the State of California. Capitalized terms contained herein shall
have the same meanings given to them in the Plan, unless otherwise provided in
this Appendix. Notwithstanding any provision contained in the Plan to the
contrary and to the extent required by applicable law, the following terms and
conditions shall apply to all Awards granted to residents of the State of
California, until such time as the Common Stock becomes a "listed security"
under the Securities Act:

     1.   Nonqualified Stock Options shall have an exercise price that is not
less than 85% of the Fair Market Value of the Common Stock at the Grant Date,
except that the exercise price shall be at least 110% of the Fair Market Value
in the case of any person who owns stock possessing more than 10% of the total
combined voting power of all classes of stock of the Company or its parent or
subsidiary corporations.

     2.   The purchase price for any Stock Awards that may be purchased under
the Plan ("Stock Purchase Rights") shall be at least 85% of the Fair Market
Value of the Common Stock at the time the Participant is granted the Stock
Purchase Right or at the time the purchase is consummated. Notwithstanding the
foregoing, the purchase price shall be at least 100% of the Fair Market Value of
the Common Stock at the time the Participant is granted the Stock Purchase Right
or at the time the purchase is consummated in the case of any person who owns
stock possessing more than 10% of the total combined voting power of all classes
of stock of the Company or its parent or subsidiary corporations.

     3.   Options shall have a term of not more than ten years from the Grant
Date.

     4.   Awards shall be nontransferable other than by will or the laws of
descent and distribution. Notwithstanding the foregoing, and to the extent
permitted by Section 422 of the Code, the Plan Administrator, in its discretion,
may permit distribution of an Option to an inter vivos or testamentary trust in
which the Option is to be passed to beneficiaries upon the death of the trustor
(settlor), or by gift to "immediate family" as that term is defined in Rule 16a-
1(e) under the Exchange Act.

     5.   Options shall become exercisable at the rate of at least 20% per year
over five years from the date the Option is granted, subject to reasonable
conditions such as continued employment. However, in the case of an Option
granted to officers, directors or consultants of the Company or any of its
affiliates, the Option may become fully exercisable, subject to reasonable
conditions such as continued employment, at any time or during any period
established by the Company or any of its affiliates.

     6.   Unless employment is terminated for Cause, the right to exercise an
Option in the event of termination of employment, to the extent that the
Participant is otherwise entitled to exercise an Option on the date employment
terminates, shall be

          a.   at least six months from the Employment Termination Date if
termination was caused by death or Disability; and

          b.   at least 30 days from the Employment Termination Date if
termination of employment was caused by other than death or Disability;

          c.   but in no event later than the remaining term of the Option.

     7.   No Award may be granted to a resident of California more than ten
years after the earlier of the date of adoption of the Plan and the date the
Plan is approved by the stockholders.

                                                                   Page 22 of 29
<PAGE>

     8.   Any Award exercised before stockholder approval is obtained shall be
rescinded if stockholder approval is not obtained within 12 months before or
after the Plan is adopted. Such shares shall not be counted in determining
whether such approval is obtained.

     9.   The Company shall provide annual financial statements of the Company
to each California resident holding an outstanding Award under the Plan. Such
financial statements need not be audited and need not be issued to key employees
whose duties at the Company assure them access to equivalent information.

     10.  Any right of repurchase on behalf of the Company in the event of a
Participant's termination of employment shall be at a purchase price that is (a)
not less than the Fair Market Value of the securities upon termination of
employment, and the right to repurchase shall be exercised for cash or
cancellation of purchase money indebtedness for the shares within 90 days of
termination of employment (or in the case of securities issued upon exercise of
Options after the date of termination, within 90 days after the date of the
exercise), and the right shall terminate when the Company's securities become
publicly traded; or (b) at the original purchase price, provided that the right
to repurchase at the original purchase price lapses at the rate of at least 20%
of the shares per year over five years from the date the Option or Stock
Purchase Right is granted (without respect to the date the Option or Stock
Purchase Right was exercised or became exercisable) and the right to repurchase
shall be exercised for cash or cancellation of purchase money indebtedness for
the shares within 90 days of termination of employment (or in the case of
securities issued upon exercise of Options after the date of termination, within
90 days after the date of the exercise). In addition to the restrictions set
forth in clauses (a) and (b), the securities held by an officer, director or
consultant of the Company or an affiliate of the Company may be subject to
additional or greater restrictions.

                                                                   Page 23 of 29
<PAGE>

                   PLAN ADOPTION AND AMENDMENTS/ADJUSTMENTS
                                 SUMMARY PAGE

<TABLE>
<CAPTION>
                                                     Section/Effect of       Date of Shareholder
Date of Board Action    Action                       Amendment               Approval
<S>                     <C>                          <C>                     <C>
September 7, 1999       Initial Plan Adoption                                June 27, 2000

May 22, 2000            Increased authorized                                 June 27, 2000
                        number of shares in
                        Section 4.1 from
                        1,000,000 to 2,000,000
                        shares

                        Added a net exercise
                        feature to Section 7.5

September 26, 2000      Plan amended and restated
                        as marked and attached to
                        the September 26, 2000
                        Board minutes, including a
                        share increase from
                        2,000,000 to 3,000,000
                        share.
</TABLE>

                                                                   Page 24 of 29

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00016-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00016-of-00352.parquet"}]]